Home › Funds › MENLO ADVISORS LLC › RPRX

MENLO ADVISORS LLC position in RPRX

ROYALTY PHARMA PLC · Health Care

MENLO ADVISORS LLC reported holding 126,940 shares of RPRX (ROYALTY PHARMA PLC) in its Q2 2026 13F filing — a position valued at US$7.1M, representing 4.95% of its reported portfolio and ranking #8 among its reported holdings. MENLO ADVISORS LLC has disclosed RPRX holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

Latest position (Q2 2026)126.94K sh
Reported value held$7.12M
Portfolio Weight4.95%
First reportedQ2 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How MENLO ADVISORS LLC's RPRX position evolved

MENLO ADVISORS LLC first disclosed a stake in RPRX in Q2 2024 at 147,885 shares (US$3.9M). The position peaked in Q2 2026 at 126,940 shares, worth US$7.1M. Across 9 filings, MENLO ADVISORS LLC increased the stake 0 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 126,940 shares valued at US$7.1M — a reduction of -700 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q2 2024 147.88K $3.90M New
Q3 2024 147.88K $4.18M Hold
Q4 2024 133.24K $3.40M Reduce
Q1 2025 133.24K $4.15M Hold
Q2 2025 131.32K $4.73M Reduce
Q3 2025 127.64K $4.50M Reduce
Q4 2025 127.64K $4.93M Hold
Q1 2026 127.64K $4.93M Hold
Q2 2026 126.94K $7.12M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RPRX and 13F data

RPRX (ROYALTY PHARMA PLC) is a Health Care company. 50 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$601.4M), Baillie Gifford & Co (US$561.6M), Caledonia (Private) Investments Pty Ltd (US$323.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RPRX

All RPRX fund holders →

FAQ

How long has MENLO ADVISORS LLC held RPRX?

MENLO ADVISORS LLC has disclosed RPRX holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

What is MENLO ADVISORS LLC's current position in RPRX?

As of Q2 2026, MENLO ADVISORS LLC holds 126.94K shares of RPRX (ROYALTY PHARMA PLC), valued at $7.12M, representing 4.95% of its reported portfolio and ranking #8.

Has MENLO ADVISORS LLC been buying or selling RPRX?

In the latest 13F filing (Q2 2026), MENLO ADVISORS LLC reduced its position in RPRX. The position peaked in Q2 2026 at 126.94K shares.

Which other funds hold RPRX?

Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, Caledonia (Private) Investments Pty Ltd, among 50 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.